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In previous studies the monoclonal antibody (MoAb) 
M2590 elicited in C57/BL6 mice with the syngeneic 
melanoma cell line Bl6 has been shown to recognize a 
31K glycoprotein expressed by human melanoma cell 
lines. The present study has shown that the MoAb 
M2590 cross-reacts with surgically removed benign and 
malignant lesions of melanocyte origin. The reactivity 
pattern of the MoAb M2590 with these lesions is differ-
ent from that of the anti-high-molecular weight-mela-
noma associated antigen (HMW-MAA) MoAb 225.288, 
of the anti-115K MAA MoAb 345.1348, and of the anti-
lOOK MAA MoAb 376.968, which were elicited with 
human melanoma cell lines. In particular, the MoAb 
M2590 reacts with blue nevi. The MoAb M2590-defined 
MAA, like other types of MAA, is heterogeneous in 
lesions removed from different patients, in autologous 
lesions removed from different anatomic sites, and in 
cells within a lesion. The distribution of the MoAb 
M2590-defined MAA in normal tissues and in tumors of 
nonmelanocyte origin is broader than that of the HMW-
MAA, but is similar to that of the 115K MAA and of the 
lOOK MAA. The results of this investigation suggest 
that immunization with xenogeneic melanoma cells may 
broaden the range of specificity of antihuman MAA 
MoAbs and provide information about the phylogenetic 
evolution of MAAs. 
The hybridoma technology has been successfully applied by 
seve ral investigato rs to develop monoclonal antibodies to hu-
man melanoma-associated antigens (MAA), i.e., antigens ex-
pressed by melanoma cells but undetectable in normal resting 
melanocytes (for review, see [1- 4]). It is a general experience 
that the ran ge of specificity of murine anti-MAA monoclonal 
antibodies (MoAb) elicited with cultured human melanoma 
ce lls is narrow (for review, see [1 - 4]). In spite of the use of 
different cell lines as immunoge ns and of different immuniza-
tion schedules, MoAbs are frequently generated against a lim -
ited number of MAAs which appear to be immunodomina nt. 
The latter include a high-molecular-weight MAA (HMW -
MAA) identified by Carrel et a l [5), Bumol and Reisfeld [6], 
Hellstrom et al [7], Ross et al (8], and ourselves [9 ,10], a 95-
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97K glycoprotein identified by Brown et a l [11] and by Dippold 
et a l [12], and a cytoplasmic MAA identified by Chee et al [13] 
and by ourselves [10,14). 
Analysis with the ava ilable anti-MAA MoAbs of surgically 
removed les ions of melanocyte origin suggests that characteri-
zation of their antigenic profile may provide useful information 
to dissect the heterogeneity of lesions with indistinguishable 
histopathologic feature s and may eventually provide markers 
to differentiate benign from malignant lesions and new criteria 
to classify melanoma lesions [15]. Since a large panel of MoAbs 
to a variety of MAAs is likely to sharpen the discriminatory 
power of immunohistochemical techniques, we are evaluating 
new approaches to generate MoAbs to yet undetected MAAs 
which have a distribution different from that of those a lready 
identified. 
Studies in the area of histocompatibility antigens have shown 
that MoAbs to murine and rat histocompatibility antigens are 
useful to analyze HLA antigens, since t hey display a specificity 
different from that of MoAbs eli cited with HLA antigens [16-
18) . These results suggest that MoAbs elicited against xenoge-
neic melanoma ce lls may be useful to characterize human 
lesions of melanocyte origin . Recently the MoAb M2590 elicited 
in C57BL/6 mice with syngeneic melanoma cells B16 has been 
shown to recognize a 31K glycoprotein expressed by human 
melanoma cells in long-term culture [19 ,20]. The molecular 
profile of the 31K MAA is different from that of MAAs iden-
tified with the avai lable MoAbs elicited with cultured human 
melanoma cells (for review, see [1-4)). The aim of this study 
was to analyze the distribution of t he determinant recognized 
by the MoAb M2590 in benign and malignant lesions of melan-
ocytic origin, in a variety of malignant tumors of different 
histotype and in normal tissues from adults and from an 8-
week-old fetus . The tissue distribution of the MoAb M2590 
defined MAA has been compared with that of 3 types of 
membrane-bound MAAs identified by our set of MoAbs elicited 
with human melanoma cells. They include the HMW-MAA 
identified by the MoAb 225.288 [10] , the 115K MAA identified 
by the MoAb 345. 134S [21), and the lOOK MAA identified by 
the MoAb 376.96S [22). 
MATERIALS AND METHODS 
Hu.ma.n and Murine Tissues 
Tissues from an 8-week-old fetus were obtained from a woman who 
underwent therapeutic abortion. Norma l and neoplastic adult tissues 
were isolated from surgically removed tumors from patients who had 
not been treated with radio- and/or chemotherapy. Biopsies of pig-
mented skin lesions were from patien ts who were receiving no therapy. 
Melanoma metastases came from patients who were receiving no ther-
apy or we re under different therapeutic regimens. 
Murine tissues were obtained from C57BL/6 mice bred at the Regina 
Elena Cancer Institute, Rome, Italy. Fetal tissues were obtained from 
animals at the 16th day of gestation. The latter was established by the 
appearance of vaginal plug. Murine melanoma cells Bl6 were obtained 
from C57BL/6 mice transplanted with this cell line. Each t issue sample 
was divided into 2 portions: one was processed for conventional histo-
pathologic di agnosis, the other one was immediately snap-frozen in 
liquid nit roge n. After a definitive histopathologic diagnosis had been 
made, 4-J.Lm cryostat sections were prepared from the frozen sample. 
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One sect ion was stained wit h O.l % toluidine blue in phosp hate bu ffer, 
pH 7.2, the ot he rs were used for indirect immunoflu orescence (IfF) 
afte r fix at ion for 10 min in cold absolute aceto ne. 
M o noclonal Antibodies and Conventional Antisera 
The prepa ration as we ll as the se rologic a nd immunochemica l cha r-
acterizatio n of the specificity of t he MoAb M2590 have been desc ribed 
e lsewhere [19]. Brielly, t.he MoAb M2590, a n lgM, is secreted by a 
h y bridoma co nstructed wit h splenocytes from C57J3.L/ 6 mi ce immu-
ni zed with synge neic mela noma cells Bl6. T esting of a la rge pane l of 
ce ll lines has detected t he dete rmin a nt recognized by the MoAb M2590 
only on murine, huma n, a nd hamster mela noma cell lines. 
Tbe a nt.i-HMW -MAA MoAb 225.28S [10], t he a n t i-115K MAA 
MoAb 345. 1:348 [21], and the a nti -lOOK MAA MoAb 376.968 [22 ] were 
pre pared a nd cha racte rized as desc ri bed elsewhere. 
Di lut ions of the MoAb were don e in phosphate (0.10 M) -buffered 
(pH 7.2) saline (0.15 M) , (PBS), conta ining 1 mg/ ml of bov ine se rum 
albumin . 
F lu orescein isoth iocya na te (F IT C) conjugate rabbi t a ntisera to 
mouse IgM a nd to mouse lgG (Cappel Lab., Cochranville, P ennsyl-
va nia ) had a flu orescein :prot.e in ratio of 3 and were used at a protein 
concentrat ion of l mg/ml. Before use the a ntisera were absorbed with 
packed AB , Rh+ erythrocytes, a nd insolubilized [23] human se rum. 
T h e a bsorbed FITC-Ia heled a nti mouse lg xenoantibodies d id not sta in 
normal t issues. Biotin -labeled goat a nt i mouse lg a nt iserum a nd FITC-
labeled avidin were purchased from T ago Inc. , Burlin game, Ca lifornia 
and Beckto n-Dickinso n, Mount View, California, respectively. Both 
r eagents we re used as suggested by t he ma nufacturer. 
Indi rect l mmuno(luorescen.ce 
IIF was pe rformed as desc ribed [ 101 h~r using MoAb solu t ions a t the 
con ce ntral ion of fi - GO l'g-f ml a nd 4 l'm-th ick acetone- fix ed ti %ue see-
t ions. This fixati on procedure was chose n s ince prelimin a ry experi -
m e nts had shown t.hat it prese rved t he most detailed fluoresce nt 
patterns. The negative co nt rols used included supernata nt from t he 
murin e myeloma cell line P3-X63-Ag-8 a nd MoAb M2.'J90 prepa ra tion 
from which t he ant ibody activity had been removed by absorption wit.h 
mela noma cells Bl6. Fluorescent patterns we re observed with a Leit.z 
Ortholux microscope equipped for phase-cont rast. microscopy and flu -
ore cent epi-illumina t.ion. Pictures were taken using a Kodak Tri -X-
Pa n film. Stained sections were examined and photographed wit hin 24 
h of t he !IF procedure because of an extensive shedding [19 ] of the 
flu orescence from t he posit ive substrates. 
T he immunofluorescence stai ning of substrates was sco red as fol -
lows: negative, when no stain was detected even with oil immersion 
objectives; ±/- , when the sta in was weakly posit ive and la rge areas 
were not sta ined; ± , when the stain was homogeneous and wea k· + 
when t he stain was homogeneous a nd inte rmediate between weak ~nd 
bright;++, wh en t he sta in was homogeneous and bright; va ria ble, when 
the staining ranged from bright to negative. 
RESULTS 
The reactivity of the MoAb M2590 was analyzed by staining 
tissues with FITC-ant imouse Ig xenoantibodies. Representa-
t ive examples of the IIF staining patterns are shown in Figs 1-
4. 
Negative tissues were retested utilizing the FITC-labeled 
avidin-biot in technique. The resul ts were superimposable. 
Reactivity of MoAb M2590 with Benign and Malignant Lesions 
of Melanocyte Origin 
Testing of t he MoAb M2590 with benign and malignant 
leswns of melanocyte origin yielded the resul ts summarized in 
Table I. 
The fluorescent sta in in both types of lesions has a punc-
tuated pattern which outlines the cell plasma membrane (Fig 
lA - F). At least 50% of each type of benign lesion includin o-
lentigo simplex was stained by MoAb M2590. The reactivit~ 
pattern of the MoAb M2590 is similar to that of the anti-
HMW -MAA MoAb 225.28S and broader t han t hat of t he anti-
FIG 1. !IF stai ning with MoAb 
M2590 and phase-cont rast. microscopy 
of benign pigmented skin lesions. T he 
staining of nevic cells of a n in t raderma l 
nevus (A and H) is homog-eneous, wh ile 
that of prolife rating epidermal melano-
cytes (white-bla.ch circles) in a compound 
nevus(C and D ) and of cells of a blue 
nevus of ce ll ula r type (E and F ) is het -
erogeneous. de= dermis, ep =epidermi s 
(A - F X 640). 
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FIG 2. IlF staining with the MoAb M2590 of melanoma lesions. 
Four-micron acetone-fixed cryostat sectionR of a superficial spreading 
melanoma (A), a nodular melanoma (8), and a metastat ic melanoma 
les ion (C) were stained with the MoAb M2590. Neop last ic ce lls display 
a fine granula r fluorescence which outlines cellular boundaries wit h 
different intensity. de= dermis, ep = ep iderm is (A -C X 640). 
115K MAA MoAb 345.1348 and of t he anti -lOOK MAA MoAb 
376.968 with intradermal junctional and compound nevi. The 
stain of these lesions by the MoAb M2590 is similar in intensity 
and distribution to that by the anti-HMW -MAA MoAb 225.288 
and stronger than that by the other two monoclonal antibodies. 
Like the HMW-MAA, the MoAb M2590-defined MAA is weak 
and heterogeneous in its expression in nests of proliferating 
epidermal melanocytes (Fig lC,D). The most striking difference 
between th is MAA and t he other three types of MAA occurs in 
common and cellular type blue nevi (Fig lE,F). All of them 
express the MoAb M2590-defined MAA, but Jack the MAA 
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recognized by the monoclonal antibodies elicited with human 
melanoma cells. 
The number of the other benign lesions tested is too limited 
to draw conclusions. The reactivity of the MoAb M2590 with 
Spitz's nevus and with spindle cell nevus is different from that 
of 2 of the 3 MoAbs tested . The latter are similar to t he MoAb 
M2590 in their reactivity with the giant nevus tested. 
The MoAb M2590 stained the majority of primary and me-
tastatic melanoma lesions tested (Fig 2A,C). There are signifi-
cant differences among the various lesions in the intensity of 
staining as well as in the percentage of cells stained. The degree 
of positivity did not correlate with the hi stogenesis of the 
lesions, t heir abi lity to produce melanin and/or their primary 
or metastatic nature. The few unreactive lesions remained 
.1egative also when the MoAb M2590 was tested at concentra-
tions ranging between 5- 50 J.Lg/ml and utilizing the avidin-
biotin method. The unreactive lesions did not differ from the 
positive ones accord ing to conventional histopathologic criteria. 
The freque ncy of the MoAb M2590-defined MAA and its 
heterogeneity among lesions as well as among cells within a 
lesion are similar to those of the HMW-MAA. It is noteworthy 
that the expression of the HMW -MAA is concordant with that 
of the MoAb M2590-detined MAA in 84% of the lesions studied. 
The frequency of the latter MAA is higher than that of the 
115K and lOOK MAAs, while t he degree of heterogeneity is 
lower. 
When tested with at least 3 autologous concurrent metastases 
from 3 patients, the MoAb M2590 displayed differential reac-
t ivity with autologous lesions from 2 patients and did not react 
with any of the 3 lesions removed from the patient BO (Table 
II). Furthermore, as shown in Table III, the MoAb M2590 
displayed differential reactivity with sequentia l metastatic le-
sions removed from 1 patient. The degree of heterogeneity of 
the MoAb M2590-defined MAA in the autologous lesions tested 
is similar to that of t he HMW-MAA and less marked than that 
of the 115K MAA and of the lOOK MAA. 
Reactivity of MoAb M2590 with Normal Fetal and Adult 
Tissu.es of Human and Murine Origin 
The MoAb M2590 was tested with normal tissues from at 
least 4 donors (age range, 35-60 years), from 2 6-month-old 
C57BL/6 mice, from 1 human, and 2 murine fetuses . The 
results obtained with human tissues are summarized in Table 
IV. The MoAb M2590-defined MAA has a highly restricted 
tissue distribution in murine fetus: it is expressed by the pig-
mented cell layer of retina and by choroid (Fig 3A ). It is not 
detected in skin, brain cortex, salivary glands, lung, stomach, 
small intestine, colon, liver, kidney, and testis. The tissue 
distribution of t he MoAb M2590-defined MAA in 6-month-old 
mjce was superimposable except for the expression by cells of 
undefined histotype scattered in the serosa of stomach and 
colon. None of the murine tissues was stained by the 3 anti-
MAA MoAbs elicited with human melanoma cell lines. The 
MoAb M2590 stained a wider spectrum of human tissues. In 
an 8-week-old fetus they include adrenal cortex, choroid, liver 
sinusoids (Fig 3B), and epithelium from small intestine. The 
positive tissues in adults include peripheral nerves (Fig 3C), 
liver sinusoids, and ep ithelia from salivary glands (Fig 3D), 
from urinary bladder, from sebaceous glands, and from lung 
bronchial glands, as well as cells of undefined histotype scat-
tered in the serosa of stomach. The fluorescence was finely 
granular around cell plasma membrane in a ll tissue substrates 
but small intestine; in the latter the apical portion of epithelium 
was stained with a linear pattern. The strongest staining was· 
observed in the epithelium of salivary glands. 
The reactivity pattern of the MoAb M2590 with both fetal 
and adult tissues is broader than that of the anti-BMW -MAA 
MoAb 225.288 and more restricted than that of the anti-115K 
MAA MoAb 345.1348 and of the anti-lOOK MAA MoAb 376.96. 
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Among fetal t issues, only isolated hair bulbs are stained by t he 
anti-HMW-MAA MoAb 225.28S. Renal proximal tubules and 
epithelial cell s of colon, small intestine, and urinary bladder, 
as well as pigment epithelium of eye were stained by the anti-
115K MAA MoAb 345.134S. Hepatocytes, ci liary body, basal 
cells in skin, and ep ithelial ce lls of cornea, of colon, of small 
intestine, and of lung were stained by t he anti-lOOK MAA 
MoAb 376.96S. 
The tissue distribution of the HMW -MAA in adults is like 
that in fetus , while that of the 115K MAA is broader and that 
of t he lOOK MAA is more restricted. The 115K MAA is ex-
pressed by endometrium, by renal proximal tubules, by basal 
cells in skin, a nd by epithelial cell s of colon, small intestine, 
stomach, prostate, salivary glands , and urinary bladder. The 
lOOK MAA is expressed only by basal cells in skin and by 
epithelial cells of stomach. 
Reactivity of the MoAb M2590 with Tumors of Nonmelanocyte 
Origin 
The reactivity pattern of the MoAb M2590 with tumors of 
nonmelanocyte origin is summarized in Table V. It should be 
noted that because of the limited amou nt of tissue available, 
not all samples of each tumor could be tested with the MoAb 
M2590 and with the other 3 anti-MAA MoAbs. Th~ MoAb 
M2590 cross-reacts with tumors of various histotype and em-
bryologic origin. The extent of this cross-reactivity is similar 
to t hat of the anti-115K MAA MoAb 345.134S and of t he anti-
lOOK MAA MoAb 376.96S and greater than t hat of the anti -
HMW-MAA MoAb 225.28S. It is noteworthy that malignant 
transformation of thyroid and endometrium may be associated 
with the appearance of the MoAb M2590-defined MAA while 
malignant t ransformation of salivary glands is accompanied by 
a loss of reactivity with the MoAb M2590. 
DISCUSSION 
In agreement with results obtained with cell lines in long-
term culture [19,20], the present investigation has shown that 
the MoAb M2590 elicited with murine melanoma cells Bl6 
cross-reacts with surgically removed melanoma lesions. At var-
iance with data obtained with cultured cell lines [19,20], testing 
FIG 3. IlF stammg with the MoAb 
M2590 of murine and human tissues. 
Four-micron acetone-fixed cryostat sec-
tions of normal murine (A), human fetal 
(B), and adult (C and D) tissues were 
stained with the MoAb M2590. The 
MoAb M2590 produces a granular stain -
ing of the pigmented layer of retina and 
choroid (arrows) of the eye removed 
from a mouse sacrificed at. the 16th day 
of intrauterine li fe (A), of the cells out-
lining the sinusoid of the liver from an 
8-week-old human fetus (B), and of the 
periphery of a nerve fiber (C) as well as 
ofparotid cells (D) from an adult donor. 
The arrow marks a node of Ranvier (A-
C X 640; D, X 1000). 
with surgically removed tissues has shown that the MoAb 
M2590 cross-reacts with tumors of various embryologic origin. 
Whether t his discrepancy reflects differences in the sensitivity 
of t he assays used with cell lines and with surgically removed 
t issues and/or loss of ant igenic determinants by cells main-
tained in long-term culture is not known at present. Whatever 
the mechanism, t hese results emphasize t he usefulness of ap-
plying immunohistochemical techniques to assess t he specific-
ity of anti-MAA MoAb, although the availability of limited 
amounts of surgically removed t issues hinders t he application 
of immunochemical approaches to define the molecular basis 
of serologic results. 
The MoAb M2590 elicited with murine melanoma cells Bl6 
displays a reactivity pattern with human benign and malignant 
lesions of melanocyte origin different from that of MoAbs 
elicited with cultured human melanoma cells. In particular the 
MoAb M2590 reacts with blue nevi. To the best of our knowl-
edge only the MoAb NK1C3 elicited with human melanoma 
cells react with blue nevi [24]. Furthermore the reactivity 
pattern of t he MoAb M2590 with a large number of benign and 
malignant melanocytic lesions removed from different patients 
and with autologous metastases is distinctly different from that 
of t he anti-115K MAA MoAb 345.134S and of the anti-lOOK 
MAA MoAb 376.96S and is similar but not superimposable to 
that of t he anti-HMW-MAA MoAb 225.288. Therefore the 
MoAb M2590 can detect an antigenic heterogeneity which 
cannot be identified with MoAbs elicited with cultured human 
melanoma cells. These results suggest t hat t he range of speci-
ficity of MoAbs useful to analyze the antigenic profile of human 
lesions of melanocyte origin can be broadened by utilizing 
reagents developed with melanoma cells from other species. 
Correlation of the antigenic phenotype with the clinical course 
of the disease will assess t he clinical significance of this infor-
mation. 
Testing of t he MoAb M2590 with a large number of normal 
and malignant tissues has shown that because of its reactivity 
with various types of tumors this antibody cannot be used to 
determine the melanoma nature of metastases with unusual 
histopathologic features. Furthermore because of its reactivity 
with several normal tissues the MoAb M2590 cannot be used 
as a carrier of radioisotopes or chemotherapeutic agents for in 
344 NATALI ET AL 
FJ<; 4. II F stain in g wit h t he MoAb M2.590 of malignant human 
tumors. Four-mi cron acelone- 11 xed c ryo.~iai sections of a rabdomyosar-
coma (A) , of a schwan noma (B), a nd or a tra nsit ional cell bladder 
ca rcinoma (C) were sta ined with the MoAb M2590. The stain ing of 
t.umor cell s is ~ronul a r a nd h et.e ro~;e n eouR (A - C X 640). 
v ivo imagin g a nd fo r immunoth e rapy. 
Like MAAs ide n t ified by m o noclonal a ntibodies elic ited with 
hum a n m e la no ma cells [2!1 ], t he M oAb M 2590-defin ed MAA is 
hete rogen eous in its expression b y t umor cells w it hin a lesio n , 
by autologous lef\ io ns, by a u tologou s lesions removed from 
d iffe re n t a nato mi c s ites fro m a give n pat ie n t, a nd by lesio ns 
removed fro m different p at ie n ts. The degree of h eterogeneity 
is s imilar t o that of t he HMW-MAA and lowe r than that of 
t he 115K MAA and of t he lOOK MAA. Furthermore t he mech -
an ism(s) underlyi n g t hi. hete roge ne ity a nd its bi ologic a nd 
clinical s ign ificance are n ot kn own at prese n t. R esul ts in anima l 
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TABLE l. Reactivity of benign and malignant lesions of rnelanoc. 'te 
origin with the an.ti-31 /( MAA MoA b M 2590 elicited with cultured 
murine melanoma cells and with the anti- HMW-MAA MoAb 225.285. 
the anti-1 15/( MAA MoA b 345. 1348, and the anti-100/( MAA MoAb 
376.96S elicited with cultured human melanoma cells 
No. 31K HMW ll5K l OOK 
cases M2590 225.288 345. 134 376.968 
Benign les ions 
Lenti go s irnple x 4 2" 3 2 4 
In tradermal nevi 13 13 13 4 6 
Junciiorwl nevi 6 5 5 4 3 
Compound nevi 8 8 8 5 5 
Blue nevi 12 12 0 0 0 
Spilz's nevus 1 1 0 0 1 
Giant. nevl!s 1 1 l I l 
Spindle cell nevus l 1 1 0 0 
Malignant. lesions 
Lentigo maligna (LM) 3 2 2 3 3 
LM melanoma 2 2 2 0 0 
Superlicial spreading (SS) 6 5 5 5 5 
SS melanoma 8 8 8 8 7 
Nodular melanoma 11 8 11 11 9 
Acral melanoma I 1 1 1 1 
Met.ast.atic melanoma 21 17 20 16 9 
• No. positive. Variable staining and +/- slaining were considered positive. 
TABLE lJ. Reactiuity of concurrent autologous melanoma metastases 
with the ant i-3 1 /( MAA MoAb M 2.590 elicited with cultured murine 
melanoma cells and with the anti-HM W-MAA MoAb 225.28S, the 
anti - ! !.'il< MAA MoAb 34.5. 134S, and the anti - lOOK MAA MoAb 

































K ey: ±/- weakly positive, large a reas negative 
± homoge neously weak sta in 
+ homogeneous stain 
++ homogeneously bright stain 








TABL E Ill. Reactivity of a prima ry lesion and of sequential metastases 
removed from a patient with nodular melan oma with the anti-31 ]( 
MAA MoAb M2590 elicited with. cultured murine melanoma cells and 
with th e anti-HMW-MAA MoAb 225.28S, the a.nti-1 15I< MAA MoAb 
345.1345, a.nd the anti-100!{ MAA MoAb 376.96S elicited with 
cultured human melanoma cells 
Date of 311< HMW 11 51< 1001< LeRion 
removal Sit.e M2590 225.288 345.1348 376.96 
Prima ry 11 -9-1981 Scalp 
metastas is 10-8- 1982 Periauricular 
(P M) region 
PM 1-3 -1983 Neck 
PM 2-14- 1983 Axilla ry 
cavity 
PMJ 9-26-1983 Subcutis 
PM 2 9-26-1983 Subcutis 
PM 3 9-26-1.983 Subcutis 
PM4 9-26-1983 Subcutis 
Key: ± homogeneously weak sta in 
+ homoge neous sta in 









v stain in g wit h hi ghly va riab le in tensity 
n.t.. not. tested 
± ± 
± 
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TABLE IV. Reactivity of human fetal and adult tissues with the anti-3 I K MAA MoAb M2590 elicited with cultured murine melanoma cen~ and 
with the anti-J-IM W -M AA MoAb 225.28S, the anti- I 15K MAA MoAb 345. I34S, and the anti· lOOK MAA MoA b 376.96S el!:cited with cultured 









Saliva ry gla nds n. t. 
Kid n ey Proxima l 
tubules 






Adre n al cortex 
Sympathetic ga nglia 








a E ight-week-old fetu s. 
b Donors' age ra nge, 35- 60 yea rs. 
Key: - negative 
v heterogeneous sta in 
+ homogeneous sta in 














Ducts n .t. 
+ n. t . 
+ n.t. 
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TABLE V. Reactivity of tumors of nonmela.nocyte origin with the anti-
3 /K MAA MoA b M2590 elicited with cultured murine melanoma cells 
and with the anti-HMW-MAA MoA b 225.28S, the anti-115K MAA 
MoA b 345. 134S, and t.hc ant£-100/C MAA M oA b 376.96S elicited with 
cultured human melanoma. cells 
Tumor rrom: 3 IK HMW 115K lOOK M2590 225.28S 345.134 376.96S 
Brain" 7/17" 0/17 2/14 1/ 13 
Saliva ry glands 0/5 1/5 1/4 0/7 
Thyroid' 3/4 0/4 1/4 0/5 
Breast 0/10 0/41 12/41 9/41 
Lung 1/6 0/6 6/10 1/8 
Stomach 1/4 0/4 0/5 0/3 
Colon 2/8 0/8 7/13 1/9 
Pancreas 0/2 0/2 n. t.d n.t. 
Liver 4/8 0/8 2/6 2/7 
Kidney 0/8 0/8 4/15 3/14 
Urin ary bladder 4/7 0/7 5/8 4/9 
Prostate 1/4 0/4 1/3 4/4 
T estis 0/2 0/2 1/2 0/3 
Endometrium 4/7 0/7 5/12 2/5 
Ovary 0/5 0/5 1/5 3/7 
Peripheral nerve 1/2 0/2 0/2 0/2 
Soft t issue 3/7 0/7 0/7 0/7 
Skin 2/10 16/37 28/37 14/37 
" The positive tumors included 1 astrocytoma, 1 ependimoblastoma, 
and 5 meningiomas. 
I> No. positive/no. tested. Variable sta ining and +/ - stainin g we re 
co nsidered posit ive. 
' The positive tumors included l follicular adenoma, 1 fo llicula r 
adenocarcinoma, and 1 papillar adenocarcinoma. 
d Not tested. 
model systems suggest that t hi s heteroge neity may play a role 
in the metastasizing properties of tumor cells [26]. 
C ross -reactivity of anti -MAA MoAbs with xenogeneic mela-
no ma ce lls is not restricted to MoAb M 2590. The anti -HMW-
MAA MoAb 225.288 has been shown to cross- react with guinea 
pig melanoma cell lines [27], t h e anti-115K MAA MoAb 
345.1348 with murine melanoma ce lls Bl6 [4], and t h e a nti-
lOOK MAA MoAb 376.96 with swine melanoma cells (C. V. 
H a mby a nd S. F e rrone, unpublished observations). This infor-
mation will contribute to our understanding of t h e phylogenetic 
evolution of human MAA and will help to select animal models 
for exp eriments that cannot be performed in humans for ethical 
reasons. 
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